We are live on ! Find out more
CCXI

ChemoCentryx, Inc.

Delisted

CCXI was delisted on the 19th of October, 2022.

100 hedge funds and large institutions have $335M invested in ChemoCentryx, Inc. in 2018 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 26 increasing their positions, 39 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more capital invested

Capital invested by funds: $141M → $335M (+$194M)

108% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 12

15% more funds holding

Funds holding: 87100 (+13)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

33% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 39

61% less call options, than puts

Call options by funds: $178K | Put options by funds: $453K

Holders
100
Holders Change
+13
Holders Change %
+14.94%
% of All Funds
2.29%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
25
Increased
26
Reduced
39
Closed
12
Calls
$178K
Puts
$453K
Net Calls
-$275K
Net Calls Change
-$362K
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$97.9M -$3.98M -386,100 -5%
BlackRock
2
BlackRock
New York
$34.9M -$1.81M -175,841 -6%
WA
3
Wasatch Advisors
Utah
$32.4M +$2.07M +201,044 +9%
Franklin Resources
4
Franklin Resources
California
$22.9M -$3.17M -307,383 -15%
Vanguard Group
5
Vanguard Group
Pennsylvania
$16.6M -$149K -14,490 -1%
FCM
6
Farallon Capital Management
California
$12.9M +$9.8M +950,000 New
Renaissance Technologies
7
Renaissance Technologies
New York
$10.5M -$973K -94,300 -11%
NCM
8
Nantahala Capital Management
Connecticut
$8.17M -$3.56M -344,586 -36%
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$7.1M +$857K +83,026 +19%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$6.26M +$4.75M +460,141 New
State Street
11
State Street
Massachusetts
$5.78M -$191K -18,468 -4%
BBA
12
Baker Bros. Advisors
New York
$5.63M +$3.77M +364,965 +744%
CG
13
Carmignac Gestion
France
$5.3M +$4.02M +390,097 New
PAM
14
Panagora Asset Management
Massachusetts
$5.03M +$901K +87,321 +31%
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$4.8M +$979K +94,889 +37%
Millennium Management
16
Millennium Management
New York
$4.41M +$704K +68,281 +27%
Northern Trust
17
Northern Trust
Illinois
$3.76M -$949 -92 -0%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$3.53M +$223K +21,606 +9%
DZ Bank
19
DZ Bank
Germany
$3.22M +$2.45M +236,992 New
PNC Financial Services Group
20
PNC Financial Services Group
Pennsylvania
$2.99M +$2.27M +219,821 New
TCIM
21
TIAA CREF Investment Management
New York
$2.88M +$932K +90,294 +75%
Goldman Sachs
22
Goldman Sachs
New York
$2.75M -$668K -64,730 -24%
OAM
23
Oxford Asset Management
United Kingdom
$2.68M -$256K -24,778 -11%
Ohio Public Employees Retirement System (OPERS)
24
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.6M +$494K +47,911 +69%
Two Sigma Investments
25
Two Sigma Investments
New York
$1.56M +$1.19M +115,073 New

CCXI Hedge Fund Activity: Q1 2018 in Review

100 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q1 2018, worth a combined $335M — up 138% from $141M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new CCXI positions and 12 closed out — a net gain of 13 holders — while 26 added to existing stakes and 39 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $9.8M. The largest seller was BVF Inc, cutting an estimated $3.98M.

  • 100 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q1 2018, up from 87 in Q4 2017.
  • Funds reported $335M of ChemoCentryx, Inc. stock for Q1 2018, up 138% quarter-over-quarter.
  • 25 funds opened new ChemoCentryx, Inc. positions in Q1 2018 and 12 closed out, a net change of +13 holders.
  • The largest ChemoCentryx, Inc. buyer in Q1 2018 was Farallon Capital Management, an estimated $9.8M added.
  • The largest ChemoCentryx, Inc. seller in Q1 2018 was BVF Inc, an estimated $3.98M sold.

Based on aggregated 13F filings for Q1 2018.